Roche nabbed a first-line approval for Avastin in brain cancer. Japanese regulators cleared the drug to treat aggressive brain tumors, including newly diagnosed glioblastoma, as monotherapy and in combination with radiation and chemo.
In what may be the first experiment of its kind, researchers have used microvesicles derived from mesenchymal bone marrow cells to treat brain cancer.
In yet another sign that the R&D side of Merck KGaA has derailed and can't get back on track, the pharma giant today said that a late-stage study of a brain cancer drug hopeful had failed to demonstrate signs of efficacy.
The U.K.'s e-Therapeutics has raised $64 million to fuel midstage clinical development of a new cancer drug, which the biotech hopes to partner on around 2017.
A team of researchers at Duke University Medical Center has created a synthetic protein, known as a BiTE (bispecific T-cell engager) that hooks together brain tumor cells and immune cells, like Velcro. This redirects the immune response to kill the cancer cells without affecting healthy cells.
A tiny particle developed by researchers at the University of New South Wales in Australia could boost the effectiveness of neuroblastoma chemotherapy.
Advanced Cancer Therapeutics will pursue further preclinical development of a possible brain cancer treatment, backed by a new NIH grant.
Stemline Therapeutics delayed its initial public offering this week, as another biotech faces a rocky road from private to public status. The oncology drug specialist planned to raise $42 million in an IPO this week at a price of $11 to $13 per share, the Nasdaq reported Tuesday, selling itself as a leader in the development of drugs that home in on cancer stem cells that are implicated in cancer recurrence.
Researchers at Northwestern Brain Tumor Institute are working to figure out whether a vaccine made from a patient's own white blood cells can be used to attack cancers by slowing the growth of tumors.
Medulloblastomas are particularly nasty cancerous brain tumors, and they are among the most common in kids. But now researchers from Dana-Farber/Children's Hospital Cancer Center, Boston Children's Hospital, Stanford University School of Medicine and elsewhere have taken a big step toward deciphering how to treat them. They've been able to link mutations in specific genes to each of four recognized subtypes of the cancer.